Atea Pharmaceuticals 

Yahoo Finance • 2 months ago

CarMax Stock Down 47% This Past Year, But One Fund Is Betting $6 Million on a Turnaround

On February 2, BML Capital Management, LLC disclosed a new position in CarMax(NYSE:KMX), acquiring 155,000 shares in an estimated $5.99 million trade based on quarterly average pricing. What happened According to an SEC filing dated Febr... Full story

Yahoo Finance • 4 months ago

Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

Enrollment Completed in C-BEYOND Phase 3 Trial with More Than 880 HCV Treatment-Naïve Patients in US and Canada C-BEYOND Topline Results Expected Mid-2026 C-FORWARD Phase 3 Trial, Conducted Outside North America, Enrollment Completion Ex... Full story

Yahoo Finance • 4 months ago

Nano Dimension And 2 Other Penny Stocks With Promising Potential

As the U.S. stock market experiences a pullback, with major indices like the Dow Jones and S&P 500 facing consecutive losses amid tech sector concerns, investors are increasingly looking for opportunities outside the mainstream. Penny stoc... Full story

Yahoo Finance • 5 months ago

Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference

BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral d... Full story

Yahoo Finance • 5 months ago

3 Promising Penny Stocks With Market Caps As Low As $200M

As the Dow Jones Industrial Average reaches new heights, closing above 48,000 for the first time amid optimism about an end to the U.S. government shutdown, investors are keenly observing market dynamics that may influence their portfolios... Full story

Yahoo Finance • 5 months ago

Atea targets mid-2026 Phase III HCV results while expanding hepatitis pipeline and maintaining $329.3M cash runway

Earnings Call Insights: Atea Pharmaceuticals (AVIR) Q3 2025 MANAGEMENT VIEW * CEO Jean-Pierre Sommadossi reported "significant progress and achievements" this quarter, highlighting the advancement of Atea's global Phase III program for... Full story

Yahoo Finance • 5 months ago

Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025

BOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral d... Full story

Yahoo Finance • 5 months ago

Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025

BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral d... Full story

Yahoo Finance • 8 months ago

Atea Pharmaceuticals Q2 2025 slides: HCV program advances with Phase 3 trials underway

Introduction & Market Context Atea Pharmaceuticals (NASDAQ:AVIR) presented its Q2 2025 corporate update on August 7, highlighting significant progress in its hepatitis C virus (HCV) treatment program and providing insights into its financ... Full story

Yahoo Finance • 8 months ago

Atea Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Patient Enrollment Advances in Global Phase 3 Program for Treatment of HCV Four Scientific Posters Presented at EASL, Including Final Results from Phase 2 Study of Bemnifosbuvir/Ruzasvir Regimen Confirming 98% Sustained Virologic Response... Full story

Yahoo Finance • 8 months ago

Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025

BOSTON, July 31, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral d... Full story

Yahoo Finance • 10 months ago

Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America

C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada Regimen has Potential Best-in-Class Profile with Short Treatment Duration... Full story

Yahoo Finance • 12 months ago

Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025

BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral... Full story

Yahoo Finance • 12 months ago

Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program

BOSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea” or “Company”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious vi... Full story

Yahoo Finance • last year

Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value

BOSTON, March 26, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral... Full story

Yahoo Finance • last year

Atea Pharmaceuticals Issues Statement Regarding Director Nominations

BOSTON, March 21, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company) a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral d... Full story

Yahoo Finance • last year

Atea Pharmaceuticals Announces Presentation of Bemnifosbuvir Preclinical Data at the 38th International Conference on Antiviral Research (ICAR) 2025

BOSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral... Full story

Yahoo Finance • last year

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Successful End-of-Phase 2 Meeting with FDA and Alignment on Phase 3 Program for Hepatitis C Virus (HCV) Patient Enrollment in Global Phase 3 HCV Program Expected to Start in April 2025 Conference Call at 4:30 pm ET Today BOSTON, March... Full story

Yahoo Finance • last year

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 6, 2025

BOSTON, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases,... Full story

Yahoo Finance • last year

Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors

BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral d... Full story